These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

589 related items for PubMed ID: 20404000

  • 21. Endocrine prevention of breast cancer using selective oestrogen receptor modulators (SORMs).
    Lo SS, Vogel VG.
    Best Pract Res Clin Endocrinol Metab; 2004 Mar; 18(1):97-111. PubMed ID: 14687600
    [Abstract] [Full Text] [Related]

  • 22. Chemoprevention of breast cancer.
    O'Regan RM.
    Cancer Treat Res; 2000 Mar; 103():183-207. PubMed ID: 10948447
    [No Abstract] [Full Text] [Related]

  • 23. Managing the risk of invasive breast cancer in women at risk for breast cancer and osteoporosis: the role of raloxifene.
    Vogel VG.
    Clin Interv Aging; 2008 Mar; 3(4):601-9. PubMed ID: 19281053
    [Abstract] [Full Text] [Related]

  • 24. [Additional effect of SERM: mammary gland].
    Kurebayashi J.
    Clin Calcium; 2004 Oct; 14(10):47-51. PubMed ID: 15577131
    [Abstract] [Full Text] [Related]

  • 25. Benefit-risk assessment of raloxifene in postmenopausal osteoporosis.
    Cranney A, Adachi JD.
    Drug Saf; 2005 Oct; 28(8):721-30. PubMed ID: 16048357
    [Abstract] [Full Text] [Related]

  • 26. Selective estrogen-receptor modulators in 2001.
    O'Regan RM, Gradishar WJ.
    Oncology (Williston Park); 2001 Sep; 15(9):1177-85, 1189-90; discussion 1190-4. PubMed ID: 11589065
    [Abstract] [Full Text] [Related]

  • 27. Update on raloxifene to prevent endometrial-breast cancer.
    Goldstein SR.
    Eur J Cancer; 2000 Sep; 36 Suppl 4():S54-6. PubMed ID: 11056320
    [Abstract] [Full Text] [Related]

  • 28. Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force.
    Kinsinger LS, Harris R, Woolf SH, Sox HC, Lohr KN.
    Ann Intern Med; 2002 Jul 02; 137(1):59-69. PubMed ID: 12093250
    [Abstract] [Full Text] [Related]

  • 29. The effect of SERMs on the endometrium.
    Goldstein SR.
    Ann N Y Acad Sci; 2001 Dec 02; 949():237-42. PubMed ID: 11795358
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk.
    Grady D, Cauley JA, Geiger MJ, Kornitzer M, Mosca L, Collins P, Wenger NK, Song J, Mershon J, Barrett-Connor E, Raloxifene Use for The Heart Trial Investigators.
    J Natl Cancer Inst; 2008 Jun 18; 100(12):854-61. PubMed ID: 18544744
    [Abstract] [Full Text] [Related]

  • 32. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation.
    Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, Farrerons J, Karasik A, Mellstrom D, Ng KW, Stepan JJ, Powles TJ, Morrow M, Costa A, Silfen SL, Walls EL, Schmitt H, Muchmore DB, Jordan VC, Ste-Marie LG.
    Breast Cancer Res Treat; 2001 Jan 18; 65(2):125-34. PubMed ID: 11261828
    [Abstract] [Full Text] [Related]

  • 33. Raloxifene in breast cancer prevention.
    Gennari L, Merlotti D, Paola VD, Nuti R.
    Expert Opin Drug Saf; 2008 May 18; 7(3):259-70. PubMed ID: 18462184
    [Abstract] [Full Text] [Related]

  • 34. [Third generation selective estrogen receptor modulators: benefits beyond bone. II, endometrial action].
    Calaf Alsina J, Coronado Martín PJ.
    Med Clin (Barc); 2013 Mar 16; 140(6):266-71. PubMed ID: 23276611
    [Abstract] [Full Text] [Related]

  • 35. Chemoprevention with antiestrogens: the beginning of the end for breast cancer. Daniel G. Miller Lecture.
    Jordan VC.
    Ann N Y Acad Sci; 2001 Dec 16; 952():60-72. PubMed ID: 11795444
    [Abstract] [Full Text] [Related]

  • 36. Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene.
    Ko SS, Jordan VC.
    Expert Opin Pharmacother; 2011 Mar 16; 12(4):657-74. PubMed ID: 21294695
    [Abstract] [Full Text] [Related]

  • 37. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
    Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, Runowicz CD, James JM, Ford LG, Wolmark N.
    J Natl Cancer Inst; 2005 Nov 16; 97(22):1652-62. PubMed ID: 16288118
    [Abstract] [Full Text] [Related]

  • 38. The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial.
    Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Wolmark N.
    Clin Breast Cancer; 2002 Jun 16; 3(2):153-9. PubMed ID: 12123540
    [Abstract] [Full Text] [Related]

  • 39. Breast cancer prevention with selective estrogen receptor modulators: a perspective.
    Pritchard KI.
    Ann N Y Acad Sci; 2001 Dec 16; 949():89-98. PubMed ID: 11795385
    [Abstract] [Full Text] [Related]

  • 40. Chemoprevention of breast cancer in the older patient.
    Minton SE.
    Hematol Oncol Clin North Am; 2000 Feb 16; 14(1):113-30. PubMed ID: 10680075
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 30.